Personalized Pathway-Activated Systems Imaging in Oncology (Запис № 446907)

МАРК-запис
000 -LEADER
fixed length control field 05607nam a22005655i 4500
001 - CONTROL NUMBER
control field 978-981-10-3349-0
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20210118125301.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 170302s2017 si | s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9789811033490
-- 978-981-10-3349-0
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-981-10-3349-0
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number R895-920
072 #7 - SUBJECT CATEGORY CODE
Subject category code MMN
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED080000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MKR
Source thema
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.07548
Edition number 23
245 10 - TITLE STATEMENT
Title Personalized Pathway-Activated Systems Imaging in Oncology
Medium [electronic resource] :
Remainder of title Principal and Instrumentation /
Statement of responsibility, etc edited by Tomio Inoue, David Yang, Gang Huang.
250 ## - EDITION STATEMENT
Edition statement 1st ed. 2017.
264 #1 -
-- Singapore :
-- Springer Singapore :
-- Imprint: Springer,
-- 2017.
300 ## - PHYSICAL DESCRIPTION
Extent XII, 243 p. 112 illus., 71 illus. in color.
Other physical details online resource.
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
347 ## -
-- text file
-- PDF
-- rda
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Part 1: Chemical Biology Aspect -- Chapter 1: PET Radiotracers for Tumor Imaging (Ming Rong Zhang) -- Chapter 2. Theranostic tracers for pathway-activated systems in oncology (Lan V. Pham, Jerry L. Bryant, David Yang, and Richard J. Ford) -- Chapter 3. Optimization of Aseptic Production in PET Radiopharmaceuticals for Compliance to the Most Current GMP (Chih-Hao K. Kao) - Part 2: Engineering and Instrumentation Aspect -- Chapter 4. OpenPET enabling PET imaging during radiotherapy (Taiga Yamaya and Hideaki Tashima) -- Chapter 5. High Resolution PET/CT development (Wai-Hoi Wong, and Yuxuan Zhang) -- Part 3: Social Aspect -- Chapter 6. Ethics, Regulations and Clinical Development of Precision Medicine: Activating with molecular imaging (Chieko Kurihara, and Tomio Inoue) -- Chapter 7. Optical Imaging: How far can we go (Wenbin Ma, Sara Herrera-Rodriguez, and Hector Martinez-Valdez) -- Part 4: Clinic Aspect -- Chapter 8. Applications of UIH High Resolution PET/CT in Zhongshan Hospital (Jun Zhou, Hongcheng Shi) -- Chapter 9. Clinical evaluation of focused high-resolution breast PET (Kanae Kawai Miyake, Yuji Nakamoto) -- Chapter 10. Recent Developments with Large-bore PET/CT (Tomohiro Kaneta, Tomio Inoue) -- Chapter 11. Copper-labeled radiopharmaceuticals in oncology (Hiroaki Kurihara) -- Chapter 12. PET radiopharmaceuticals in oncology beyond FDG (Shao-Li Song, Pan-Li Li, Gang Huang) -- Chapter 13. Molecular Imaging in Oncology: Challenges and Opportunities in 21st Century (Ya-Ming Li, Ya-Ming Li, David J. Yang, and Xue-Na Li) -- Chapter 14. Visualization of Apoptosis: Annexin V imaging (Skye Hsin-Hsien Yeh, Fan-Lin Kong, Ming-Hsien Lin).
520 ## - SUMMARY, ETC.
Summary, etc This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed. Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agents have potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome. This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists—molecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff.
506 ## - RESTRICTIONS ON ACCESS NOTE
Terms governing access Available to subscribing member institutions only. Доступно лише організаціям членам підписки.
506 ## - RESTRICTIONS ON ACCESS NOTE
Standardized terminology for access restriction Online access from local network of NaUOA.
506 ## - RESTRICTIONS ON ACCESS NOTE
Standardized terminology for access restriction Online access with authorization at https://link.springer.com/
506 ## - RESTRICTIONS ON ACCESS NOTE
Standardized terminology for access restriction Онлайн-доступ з локальної мережі НаУОА.
506 ## - RESTRICTIONS ON ACCESS NOTE
Standardized terminology for access restriction Онлайн доступ з авторизацією на https://link.springer.com/
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Nuclear medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Oncology  .
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Nuclear Medicine.
-- http://scigraph.springernature.com/things/product-market-codes/H29048
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Oncology.
-- http://scigraph.springernature.com/things/product-market-codes/H33160
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Inoue, Tomio.
Relator term editor.
Relator code edt
-- http://id.loc.gov/vocabulary/relators/edt
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Yang, David.
Relator term editor.
Relator code edt
-- http://id.loc.gov/vocabulary/relators/edt
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Huang, Gang.
Relator term editor.
Relator code edt
-- http://id.loc.gov/vocabulary/relators/edt
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9789811033483
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9789811033506
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9789811098505
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1007/978-981-10-3349-0">https://doi.org/10.1007/978-981-10-3349-0</a>
912 ## -
-- ZDB-2-SME
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type ЕКнига

Немає доступних примірників.